Group 1: Financial Performance - The company's profit has significantly improved year-on-year due to three main factors: 1. The conductive film business structure optimization led to revenue growth, with the gaming touch button field generating revenue of 98.73 million, up 22.83% year-on-year [1] 2. The sales of dimmable conductive films in automotive applications reached 66.95 million, increasing by 122.70% year-on-year [1] 3. The 2A/3A optical film products achieved revenue of 29.45 million, a year-on-year growth of 104.19% [2] Group 2: Product Development and Market Trends - The embedded in-cell technology has improved the thickness by 0.3mm and increased light transmittance by 15%, with the yield rate rising from 65% three years ago to 88% in 2024, driving the penetration rate of LCD mobile phones to over 75% [2] - The company has established four major technology platforms for dimmable conductive films, focusing on automotive applications such as sunroofs and side windows [2][3] Group 3: Competitive Landscape and Future Outlook - The main competitors in the dimmable conductive film market include EC, SPD, LC, and PDLC technologies, with the company primarily focusing on EC electrochromic technology [3] - The OCA optical adhesive product has seen a revenue of 158 million, growing by 21.3% year-on-year, but has not yet achieved profitability due to market price competition and high R&D costs [5]

A 股每股现金红利0.85元 证券代码：603297 证券简称：永新光学 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/13 | － | 2025/6/16 | 2025/6/16 | | ? 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经宁波永新光学股份有限公司（以下简称"公司"）2025 年 5 月 20 日 的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，扣除拟回购注销的限制性股票 213,800 股 后，在中国证券登记结算有限责任公司上海分公司（以下简称"中国结算上海分公司"）登记 在册的本公司全体股东。 根据公司 2024 年年度股东大会审议通过的《2024 年度利润分配 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Group 1 - The public fund industry continues to focus on high-intensity research, particularly in hard technology and pharmaceuticals, with 123 public fund institutions conducting 662 research sessions on 112 A-shares in the first week of June [1] - The optical and optoelectronic industry, represented by Hongjing Optoelectronics (301479), received the most attention, with over 20% of public fund institutions participating in 36 research sessions [1] - A total of 22 secondary industries received at least 10 research sessions, indicating a concentrated interest in specific sectors [1] Group 2 - The optical and optoelectronic industry had the highest research activity, with 7 stocks collectively receiving 72 sessions, followed by the chemical pharmaceutical industry with 59 sessions across 6 stocks [2] - The jewelry industry saw a notable increase in attention, with companies like Cuihua Jewelry and Mankalon receiving a total of 46 research sessions [2] - Public fund institutions are increasingly focusing on technology, pharmaceuticals, and consumer upgrades, reflecting current market conditions [2] Group 3 - Yifan Pharmaceutical (002019) discussed its innovative drug development during institutional research, emphasizing the importance of cautious and rational approaches to R&D, particularly for First-in-Class (FIC) drugs [3] - The company is prioritizing the development of its drug F-652 for alcohol-related liver disease in collaboration with U.S. research institutions, while also evaluating risks and opportunities [3] - Yifan Pharmaceutical is also advancing early-stage products like IL-15 fusion protein, which are still in the early research phase [3]

2025 年 06 月 08 日 北证专精特新（899601）：小而精， 特色更鲜明的优质投资标的 ——北交所发布北证专精特新指数点评 证券分析师 刘靖 A0230512070005 liujing@swsresearch.com 研究支持 吕靖华 A0230124070002 lvjh@swsresearch.com 联系人 吕靖华 (8621)23297818× lvjh@swsresearch.com 策 略 研 究 证 本研究报告仅通过邮件提供给 中庚基金 使用。1 请务必仔细阅读正文之后的各项信息披露与声明 A 股 策 资料来源：Wind，申万宏源研究；截至 2025/6/6 资料来源：Wind，申万宏源研究；截至 2025/6/6 略 券 研 究 报 告 ⚫ 事件：2025 年 6 月 6 日，北交所公告将于 2025 年 6 月 30 日正式发布北证专精特新指 数，经流动性筛选后，北证专精特新指数将从符合条件的北交所专精特新"小巨人"上市 公司中选取市值最大的 50 只作为指数样本，为市场提供多维度投资标的和业绩基准。 ⚫ 北证专精特新聚焦小巨人、特色更鲜明，编制规则采用半年度调仓、调整数量不超 ...

Core Viewpoint - BOE Technology Group Co., Ltd. is experiencing positive market movements with a recent stock price increase and significant institutional interest, indicating a favorable outlook for the company and the LCD industry overall [1][2]. Group 1: Trading Information - As of June 6, 2025, BOE A shares closed at 3.94 CNY, up 3.68% from the previous week [1]. - On June 6, a block trade occurred with institutional net purchases amounting to 202.12 thousand CNY [2]. Group 2: Industry Insights - The LCD industry is seeing a normalization in supply and demand, with manufacturers adopting a "production based on demand" strategy, leading to a reduction in inventory levels [3]. - The mainstream LCD TV panel prices have been rising since January 2025, but demand is expected to cool down in the second quarter, stabilizing prices in May [3]. Group 3: Company Developments - BOE has made significant progress in its flexible AMOLED business, establishing a competitive edge in production capacity and technology, and is actively engaging with major smartphone brands [3]. - The Chengdu 8.6-generation AMOLED production line project has commenced equipment installation four months ahead of schedule, transitioning from construction to operational phase [4]. - The company anticipates a depreciation expense of approximately 38 billion CNY in 2024, with depreciation expected to peak this year as new projects come online and older lines reach the end of their depreciation period [4]. Group 4: Financial Announcements - BOE has received a loan commitment of 1.8 billion CNY from China Construction Bank for stock repurchase purposes, with a loan term of three years [5].

□业绩说明会 □媒体采访 □现场参观 证券代码：873001 证券简称：纬达光电 公告编号：2025-045 佛山纬达光电材料股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 √特定对象调研 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 6 月 5 日 活动地点：公司会议室 参会单位及人员：银河证券、深圳纽富斯投资管理有限公司、深圳德毅资产 管理公司、深圳狄道投资、广东圆澄私募证券投资基金、奕廷私募基金、广东大 兴华旗资产管理公司、广州三合泰私募股权投资基金及其他个人投资者，共计 22 人 上市公司接待人员：公司董事长刘燕婷，公司董事、总经理李铭全，公司副 总经理、财务总监、董事会秘书赵刚涛 三、 投资者关系活动主要内容 2025 年 6 月 5 日，广新集团 2025 年"走进上市公司"系列活动——北交所 上市公司投资者调研活动顺利在公司现场举行，活动中公司针对投资者提出的问 题进行沟通交流 ...

Core Insights - The stock of 8Yuan Shikong (688181) shows a strong overall score of 52.96, indicating a robust performance in the market [1] - The stock price has recently breached its short-term support level, suggesting a cautious approach for short-term investors while waiting for the main funds to choose a direction [2][4] Price and Cost Analysis - Current main force costs are reported as follows: 29.53 CNY for the day, 29.71 CNY for 5 days, 29.69 CNY for 20 days, and 28.44 CNY for 60 days [1] - The stock has experienced one limit-up and one limit-down in the past year [1] Technical Analysis - Short-term pressure level is at 30.84 CNY, while short-term support is at 30.95 CNY [2] - The mid-term pressure level is 28.74 CNY, and the mid-term support level is not clearly defined [2] Fund Flow Data - On June 6, 2025, the net outflow of main funds was 716.05 thousand CNY, accounting for 18% of the total transaction volume [2] - There was no net inflow from large orders, while retail investors contributed a net inflow of 12.55 thousand CNY [2] Financial Data - Earnings per share (EPS) is reported at 0.18 CNY, with an operating profit of 30 million CNY [3] - The net profit stands at approximately 23.04 million CNY, and the sales gross margin is 42.626% [3]

从中证港美上市全球智能驾驶主题指数持仓样本的行业来看，乘用车占比22.53%、数字媒体占比 2.98%、光学光电子占比2.66%、汽车零部件与轮胎占比0.33%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 本文源自：金融界 作者：行情君 据了解，中证港美上市全球智能驾驶主题指数从中国香港和美国市场上市的证券中选取50只业务涉及感 知定位、决策规划、控制执行以及车联网等智能驾驶相关领域的上市公司证券作为指数样本，反映中国 香港和美国市场上市的智能驾驶主题上市公司证券的整体表现。该指数以2016年12月30日为基日，以 1000.0点为基点。 从指数持仓来看，中证港美上市全球智能驾驶主题指数十大权重分别为：NVIDIA Corp（10.74%）、理 想汽车-W（9.89%）、Tesla Motors In ...

Investment Rating - The report maintains a "Buy" rating for the company [7][12]. Core Insights - The company is expected to achieve revenue of 6.278 billion yuan in 2024, representing a year-on-year growth of 23.67%, and a net profit of 1.030 billion yuan, reflecting a significant increase of 71.57% [2][10]. - The company has diversified its product offerings, with all five major business segments showing positive growth, particularly in optical components and film optical panels, which contributed significantly to the main revenue [2][3]. - The company has established a global presence with six production bases and is actively expanding its international market reach, enhancing its collaboration with major clients [3][5]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are 7.346 billion yuan, 8.596 billion yuan, and 10.059 billion yuan, respectively, with corresponding net profits of 1.207 billion yuan, 1.416 billion yuan, and 1.664 billion yuan [7][10]. - The company's PE ratios for 2025, 2026, and 2027 are projected to be 22 times, 19 times, and 16 times, respectively [7][10]. Business Strategy - The company has acquired a 95.60% stake in Guangdong Aikesi, enhancing its strategic development in the AR/VR sector and positioning itself as a comprehensive optical solution provider [6][7]. - The company is transitioning from a product-driven model to a technology innovation-driven model, aiming to become a leading optical solution supplier [5][6].